This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Revefenacin

Theravance Biopharma, Inc.

Drug Names(s): GSK1160724, TD-4208

Description: GSK1160724 is an inhaled, long-acting muscarinic antagonist (LAMA) being developed in a nebulized formulation. Inhaled muscarinic antagonists block the effect of acetylcholine at its muscarinic receptor, leading to airway smooth muscle relaxation and bronchodilation.

Deal Structure: In March 2004, Theravance entered into a strategic alliance with GSK for the development and commercialization of product candidates in a variety of therapeutic areas. In connection with the strategic alliance, the Company received a $20.0 million payment from GSK in May 2004.

The alliance provides GSK with an option to license product candidates from the Companys full drug discovery programs initiated prior to September 1, 2007 on pre-determined terms and on an exclusive, worldwide basis. Upon licensing a program, GSK is responsible for funding all future development, manufacturing and commercialization activities for product candidates in that program. Consistent with the Companys strategy, the Company is obligated at its sole cost to discover two structurally different product candidates for any programs that are licensed by GSK under the alliance. If these programs are successfully advanced through development by GSK, the Company is entitled to receive clinical,...See full deal structure in Biomedtracker

Partners: Mylan Inc.


Revefenacin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug